A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803

Summary

This is a single-blind, randomized, comparative, phase I study to evaluate the tolerability, safety and pharmacokinetic characteristics of human chorionic gonadotropin between two recombinant hCG products named DA-3803 injection and ovidrel liquid injection, in healthy subjects. The subjects will injected with these two injections at the the 21day-interval of time and their conditions including vital signs, blood, clinical examination will be carefully observed.

Timeline

Start

2010-05

Primary completion

2010-08

Completion

2011-04

Drugs

Indications